Pfizer Ltd. agreed to acquire the Neksium brand in India from AstraZeneca PLC's Swedish unit AstraZeneca AB for 750 million Indian rupees.
India-based Pfizer said the acquisition of the brand will complement its existing product portfolio in the gastrointestinal therapeutic area.
The closing of the transaction is subject to customary closing conditions.